GLP-1 Research Literature

Glucagon-like peptide-1 changed everything researchers thought they knew about appetite regulation. Originally identified as a gut hormone released after eating, GLP-1 has become arguably the most intensely studied peptide in modern metabolic research — with thousands of published papers and multiple Nobel Prize-winning discoveries tied to its mechanisms.

The research interest is straightforward: GLP-1 receptor activation triggers a cascade of metabolic effects that researchers have documented extensively. It slows gastric emptying, increases insulin secretion in response to glucose, and — most notably — acts directly on the hypothalamus to suppress appetite signaling.

A landmark 2025 meta-analysis published in Diabetes Care examined 47 randomized controlled trials involving 23,244 participants. Across all studies, GLP-1 receptor agonists produced a mean weight reduction of 4.57 kilograms, a mean BMI reduction of 2.07 kg/m², and significant reductions in waist circumference compared to placebo groups.

But those are averages across many different compounds and dosing protocols. Individual study results have been far more dramatic. A real-world retrospective study of 2,405 patients published in 2023 tracked outcomes over 72 weeks and documented progressive weight reduction starting at 1.1% body weight at 8 weeks and increasing to 2.2% at 72 weeks — with the trajectory still declining at the study endpoint.

One of the earliest and most cited human studies on GLP-1 and appetite was published by Näslund and colleagues. In a randomized, blinded crossover study, eight subjects with BMIs averaging 45.5 received an intravenous infusion of GLP-1 at 0.75 picomoles per kilogram per minute or saline placebo for 8 hours. The researchers measured food intake at lunch and dinner.

The results were clear: GLP-1 infusion significantly reduced total energy intake at both meals. The researchers used visual analogue scales to track hunger and fullness throughout the day and documented sustained appetite suppression across the entire infusion period.

A 2023 systematic review of randomized clinical trials across PubMed, Scopus, and ScienceDirect examined the effects of GLP-1 analogues specifically on appetite parameters, gastric emptying, food preference, and taste sensitivity. The researchers found consistent appetite suppression and delayed gastric emptying across studies, with some evidence of altered food preference patterns.

GLP-1 research extends well beyond appetite and weight. Published studies have documented improvements in blood pressure, triglycerides, LDL cholesterol, total cholesterol, HbA1c, and fasting glucose — all measured as exploratory or secondary endpoints in weight management trials. A meta-analysis of eating disorder studies found that GLP-1 agonists reduced Binge Eating Scale scores by 8.14 points and waist circumference by 3.14 centimeters compared to controls.

GLP-1 is a single-receptor agonist — it targets one receptor pathway. Newer research compounds like GLP-2 (tirzepatide) target two receptors (GLP-1 and GIP), while GLP-3RT (retatrutide) targets three receptors (GLP-1, GIP, and glucagon). Each additional receptor adds different metabolic pathways. Published trial data shows progressively greater effects as receptor coverage increases, which is why multi-receptor compounds have generated enormous research interest.